Literature DB >> 25946987

Multiple Sclerosis and T Lymphocytes: An Entangled Story.

Laurine Legroux1, Nathalie Arbour2.   

Abstract

Multiple sclerosis (MS) is the prototypic inflammatory disease of the central nervous system (CNS) characterized by multifocal areas of demyelination, axonal damage, activation of glial cells, and immune cell infiltration. Despite intensive years of research, the etiology of this neurological disorder remains elusive. Nevertheless, the abundance of immune cells such as T lymphocytes and their products in CNS lesions of MS patients supports the notion that MS is an immune-mediated disorder. An important body of evidence gathered from MS animal models such as experimental autoimmune encephalomyelitis (EAE), points to the central contribution of CD4 T lymphocytes in disease pathogenesis. Both Th1 (producing interferon-γ) and Th17 (producing interleukin 17) CD4 T lymphocytes targeting CNS self-antigens have been implicated in MS and EAE pathobiology. Moreover, several publications suggest that CD8 T lymphocytes also participate in the development of MS lesions. The migration of activated T lymphocytes from the periphery into the CNS has been identified as a crucial step in the formation of MS lesions. Several factors promote such T cell extravasation including: molecules (e.g., cell adhesion molecules) implicated in the T cell-blood brain barrier interaction, and chemokines produced by neural cells. Finally, once in the CNS, T lymphocytes need to be reactivated by local antigen presenting cells prior to enter the parenchyma where they can initiate damage. Further investigations will be necessary to elucidate the impact of environmental factors (e.g., gut microbiota) and CNS intrinsic properties (e.g., microglial activation) on this inflammatory neurological disease.

Entities:  

Keywords:  Autoimmunity; Central nervous system; Demyelination; Neurodegeneration; Neuroinflammation; T lymphocytes

Mesh:

Year:  2015        PMID: 25946987      PMCID: PMC5052065          DOI: 10.1007/s11481-015-9614-0

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  258 in total

1.  Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells.

Authors:  Ingunn M Stromnes; Lauren M Cerretti; Denny Liggitt; Robert A Harris; Joan M Goverman
Journal:  Nat Med       Date:  2008-02-17       Impact factor: 53.440

2.  Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis.

Authors:  C L Vanderlugt; K L Neville; K M Nikcevich; T N Eagar; J A Bluestone; S D Miller
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

3.  Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412.

Authors:  N Llewellyn-Smith; M Lai; D H Miller; P Rudge; A J Thompson; M L Cuzner
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

Review 4.  T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  J M Fletcher; S J Lalor; C M Sweeney; N Tubridy; K H G Mills
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

Review 5.  Mucosal-associated invariant T cells: unconventional development and function.

Authors:  Lionel Le Bourhis; Lucia Guerri; Mathilde Dusseaux; Emmanuel Martin; Claire Soudais; Olivier Lantz
Journal:  Trends Immunol       Date:  2011-04-02       Impact factor: 16.687

6.  B7H1-Ig fusion protein activates the CD4+ IFN-gamma receptor+ type 1 T regulatory subset through IFN-gamma-secreting Th1 cells.

Authors:  Qing Ding; Liming Lu; Baolong Wang; Yun Zhou; Yang Jiang; Xiaorong Zhou; Lijun Xin; Zhijun Jiao; Kuang-Yen Chou
Journal:  J Immunol       Date:  2006-09-15       Impact factor: 5.422

7.  Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid.

Authors:  J Mellergård; M Edström; M Vrethem; J Ernerudh; C Dahle
Journal:  Mult Scler       Date:  2009-12-09       Impact factor: 6.312

8.  Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome.

Authors:  Paolo Giannetti; Marios Politis; Paul Su; Federico E Turkheimer; Omar Malik; Shiva Keihaninejad; Kit Wu; Adam Waldman; Richard Reynolds; Richard Nicholas; Paola Piccini
Journal:  Brain       Date:  2014-11-21       Impact factor: 13.501

9.  MHC class I-restricted myelin epitopes are cross-presented by Tip-DCs that promote determinant spreading to CD8⁺ T cells.

Authors:  Qingyong Ji; Luca Castelli; Joan M Goverman
Journal:  Nat Immunol       Date:  2013-01-06       Impact factor: 25.606

10.  The relation between inflammation and neurodegeneration in multiple sclerosis brains.

Authors:  Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

View more
  58 in total

1.  1,25-dihydroxyvitamin D3 -induced dendritic cells suppress experimental autoimmune encephalomyelitis by increasing proportions of the regulatory lymphocytes and reducing T helper type 1 and type 17 cells.

Authors:  Zhongxiang Xie; Jingtao Chen; Chao Zheng; Jing Wu; Yun Cheng; Shan Zhu; Chenhong Lin; Qingqing Cao; Jie Zhu; Tao Jin
Journal:  Immunology       Date:  2017-07-10       Impact factor: 7.397

2.  The Spatio-Temporal Expression Profiles of CD4 + T Cell Differentiation and Function-Related Genes During EAE Pathogenesis.

Authors:  Yingying Cai; Hu Shen; Chaoyan Qin; Jinfeng Zhou; Weiming Lai; Juping Pan; Changsheng Du
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

Review 3.  The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface.

Authors:  Ariel D Stock; Sivan Gelb; Ofer Pasternak; Ayal Ben-Zvi; Chaim Putterman
Journal:  Autoimmun Rev       Date:  2017-04-17       Impact factor: 9.754

4.  Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers.

Authors:  C De Andres; M I García; H Goicoechea; M L Martínez-Ginés; J M García-Domínguez; M L Martín; F Romero-Delgado; A Benguría; M Sanjurjo; L A López-Fernández
Journal:  Pharmacogenomics J       Date:  2016-09-27       Impact factor: 3.550

Review 5.  Vitamin D and Genetic Susceptibility to Multiple Sclerosis.

Authors:  Concetta Scazzone; Luisa Agnello; Giulia Bivona; Bruna Lo Sasso; Marcello Ciaccio
Journal:  Biochem Genet       Date:  2020-11-07       Impact factor: 1.890

6.  Soluble antigen arrays disarm antigen-specific B cells to promote lasting immune tolerance in experimental autoimmune encephalomyelitis.

Authors:  Brittany L Hartwell; Chad J Pickens; Martin Leon; Laura Northrup; Matthew A Christopher; J Daniel Griffin; Francisco Martinez-Becerra; Cory Berkland
Journal:  J Autoimmun       Date:  2018-07-13       Impact factor: 7.094

7.  Intracranial delivery of interleukin-17A via adeno-associated virus fails to induce physical and learning disabilities and neuroinflammation in mice but improves glucose metabolism through AKT signaling pathway.

Authors:  Junling Yang; Jinghong Kou; Jeong-Eun Lim; Robert Lalonde; Ken-Ichiro Fukuchi
Journal:  Brain Behav Immun       Date:  2015-11-10       Impact factor: 7.217

8.  Co-delivery of autoantigen and dexamethasone in incomplete Freund's adjuvant ameliorates experimental autoimmune encephalomyelitis.

Authors:  Laura Northrup; J Daniel Griffin; Matthew A Christopher; Lorena R Antunez; Brittany L Hartwell; Chad J Pickens; Cory Berkland
Journal:  J Control Release       Date:  2017-09-28       Impact factor: 9.776

9.  β1-Integrin- and KV1.3 channel-dependent signaling stimulates glutamate release from Th17 cells.

Authors:  Katharina Birkner; Beatrice Wasser; Tobias Ruck; Carine Thalman; Dirk Luchtman; Katrin Pape; Samantha Schmaul; Lynn Bitar; Eva-Maria Krämer-Albers; Albrecht Stroh; Sven G Meuth; Frauke Zipp; Stefan Bittner
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

10.  Immunomodulation By Subchronic Low Dose 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in Experimental Autoimmune Encephalomyelitis in the Absence of Pertussis Toxin.

Authors:  Eun-Ju Yang; John V Stokes; Evangel Kummari; Jeffrey Eells; Barbara L F Kaplan
Journal:  Toxicol Sci       Date:  2016-01-27       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.